StreetInsider.com News Articles

iShares Nasdaq Biotechnology (IBB) call put ratio 1.3 calls to 1 put into the annual J.P. Morgan Healthcare Conference

Thu, 08 Jan 2026 11:10:08 -0500

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 21; compared to its 52-week range of 17 to 46. Call put ratio 1.3 calls to 1 put into the annual J.P. Morgan Healthcare Conference.

Buy this biotech stock ahead of underdog commercial launch

Fri, 17 Oct 2025 08:00:00 -0500

Bank of America, in a Thursday note, flagged a “rare (disease) opportunity,” as it initiated coverage on a biotech stock it believes is set up for an underappreciated commercial launch.

While the broader sector has seen sharp swings this year, the upcoming catalysts tied to a novel autoimmune therapy create a setup that could unlock substantial equity upside.

The bank is referring to Vera Therapeutics (NASDAQ: VERA), whose lead drug atacicept targets IgA nephropathy, a rare kidney disorder with a peak market opportunity estimated at around $15 billion.

BofA started coverage on the stock with a Buy rating and a $48 price objective,

Buy this biotech stock ahead of underdog commercial launch

Fri, 17 Oct 2025 08:00:00 -0500

Bank of America, in a Thursday note, flagged a “rare (disease) opportunity,” as it initiated coverage on a biotech stock it believes is set up for an underappreciated commercial launch.

While the broader sector has seen sharp swings this year, the upcoming catalysts tied to a novel autoimmune therapy create a setup that could unlock substantial equity upside.

The bank is referring to Vera Therapeutics (NASDAQ: VERA), whose lead drug atacicept targets IgA nephropathy, a rare kidney disorder with a peak market opportunity estimated at around $15 billion.

BofA started coverage on the stock with a Buy rating and a $48 price objective,

Buy this biotech stock ahead of underdog commercial launch

Fri, 17 Oct 2025 08:00:00 -0500

Bank of America, in a Thursday note, flagged a “rare (disease) opportunity,” as it initiated coverage on a biotech stock it believes is set up for an underappreciated commercial launch.

While the broader sector has seen sharp swings this year, the upcoming catalysts tied to a novel autoimmune therapy create a setup that could unlock substantial equity upside.

The bank is referring to Vera Therapeutics (NASDAQ: VERA), whose lead drug atacicept targets IgA nephropathy, a rare kidney disorder with a peak market opportunity estimated at around $15 billion.

BofA started coverage on the stock with a Buy rating and a $48 price objective,

Buy this biotech stock ahead of underdog commercial launch

Fri, 17 Oct 2025 08:00:00 -0500

Bank of America, in a Thursday note, flagged a “rare (disease) opportunity,” as it initiated coverage on a biotech stock it believes is set up for an underappreciated commercial launch.

While the broader sector has seen sharp swings this year, the upcoming catalysts tied to a novel autoimmune therapy create a setup that could unlock substantial equity upside.

The bank is referring to Vera Therapeutics (NASDAQ: VERA), whose lead drug atacicept targets IgA nephropathy, a rare kidney disorder with a peak market opportunity estimated at around $15 billion.

BofA started coverage on the stock with a Buy rating and a $48 price objective,

iShares Nasdaq Biotechnology (IBB) 30-day option implied volatility as share price up

Thu, 02 Oct 2025 04:43:18 -0500

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 22; compared to its 52-week range of 16 to 46 as share price up.

iShares Nasdaq Biotechnology (IBB) 30-day option implied volatility low, share price up 2.2%

Wed, 01 Oct 2025 10:22:32 -0500

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 20; compared to its 52-week range of 16 to 46 as share price up 2.2%.

iShares Nasdaq Biotechnology (IBB) call put ratio 1 call to 1.7 puts

Tue, 08 Jul 2025 03:02:38 -0500

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 22; compared to its 52-week range of 16 to 46. Call put ratio 1 call to 1.7 puts.

Pharma stocks recover from initial shock of Trump's drug pricing order

Mon, 12 May 2025 07:15:46 -0500

By Sriparna Roy and Joel Jose

(Reuters) -Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's sweeping executive order to slash prescription drug prices would be difficult to implement and face legal challenges.

Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of

Pharma stocks recover from initial shock of Trump's drug pricing order

Mon, 12 May 2025 07:15:46 -0500

By Sriparna Roy and Joel Jose

Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of

Exclusive-US pharma tariffs would raise US drug costs by $51 billion annually, report finds

Fri, 25 Apr 2025 09:53:01 -0500

By Maggie Fick

LONDON (Reuters) -A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.

The analysis, conducted by Ernst & Young, found the United States imported $203

Exclusive-US pharma tariffs would raise US drug costs by $51 billion annually, report finds

Fri, 25 Apr 2025 09:53:01 -0500

By Maggie Fick

The analysis, conducted by Ernst & Young, found the United States imported $203

FDA To Limit Industry Employees From Its Advisory Committees

Thu, 17 Apr 2025 15:36:04 -0500

In keeping with U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr.’s promise to carry out the Department’s work with “radical transparency” and mitigate perceived industry influence and conflicts of interests, FDA Commissioner Martin A. Makary, M.D., M.P.H., announces a policy directive that limits individuals employed at companies regulated by the U.S. Food and Drug Administration, such as pharmaceutical companies, from serving as official members on FDA advisory committees, where statutorily allowed. As part of this effort, the agency will prioritize and elevate the role of patients and caregivers, strengthening the voices of their communities.

The FDA uses

FDA To Limit Industry Employees From Its Advisory Committees

Thu, 17 Apr 2025 15:36:04 -0500

The FDA uses

iShares Nasdaq Biotechnology (IBB) call put ratio 1 call to 4.4 puts as share price down 2.4%

Mon, 31 Mar 2025 11:21:31 -0500

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 24; compared to its 52-week range of 15 to 18. Call put ratio 1 call to 4.4 puts as share price down 2.4%.

Increasing unusual option volume: PRGO FE ACHC IBB ALGM CRBG RC RSI EU ITW

Tue, 04 Mar 2025 05:37:55 -0500

Increasing unusual option volume: PRGO FE ACiShares Nasdaq Biotechnology (NASDAQ: IBB)
HC IBB ALGM CRBG RC RSI EU ITW

iShares Nasdaq Biotechnology (IBB) spreader of 36K contracts of March 126 and March 127 puts

Mon, 10 Feb 2025 05:18:40 -0500

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 20; compared to its 52-week range of 15 to 31 amid a spreader of 36K contracts of March 126 and March 127 puts.

iShares Nasdaq Biotechnology (IBB) call put ratio 2.4 calls to 1 put into the annual J.P. Morgan Healthcare Conference

Wed, 08 Jan 2025 05:45:06 -0500

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 21; compared to its 52-week range of 15 to 30. Call put ratio 2.4 calls to 1 put into the annual J.P. Morgan Healthcare Conference.

Altimmune (ALT) Added to Nasdaq Biotechnology Index